๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes

โœ Scribed by Griffin, M.E.; McInerney, D.; Fraser, A.; Johnson, A.H.; Collins, P.B.; Owens, D.; Tomkin, G.H.


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
149 KB
Volume
14
Category
Article
ISSN
0742-3071

No coin nor oath required. For personal study only.

โœฆ Synopsis


Autoantibodies to oxidized low density lipoprotein have been shown to be an independent predictor of the progression of carotid atherosclerosis. This study examines the relationship between low density lipoprotein fatty acid composition and autoantibodies to both malondialdehyde-modified and copper-oxidized low density lipoprotein in non-diabetic patients with (n = 17), and without (n = 18), definite evidence of previous myocardial infarction. The third group were non-insulin-dependent diabetic patients with no evidence of atherosclerosis (n = 15) and the fourth group were patients with non-insulin-dependent diabetes (n = 17) who had definite evidence of previous myocardial infarction. Fatty acids were measured by gas-liquid chromatography. Antibodies to malondialdehyde-modified low density lipoprotein and copper-oxidized low density lipoprotein were determined by an ELISA method. Autoantibodies to copper-oxidized low density lipoprotein were significantly higher in the non-diabetic patients with heart disease when compared to any other group (p ฯฝ 0.05). Autoantibodies to malondialdehyde-modified low density lipoprotein were significantly higher in the non-diabetic subjects with heart disease and in both diabetic groups compared to non-diabetic subjects without coronary heart disease (p ฯฝ 0.05). Linoleic acid (%) in low density lipoprotein did not differ between groups but arachidonic acid (%) was significantly lower in both diabetic and non-diabetic patients with coronary heart disease (p ฯฝ 0.05). The diabetic patients with low antibodies had 39.6 ยฑ 2.2 % polyunsaturated fatty acids in their low density lipoprotein while diabetic patients with high antibodies had 46.7 ยฑ 1.2 % polyunsaturates in their low density lipoprotein (p ฯฝ 0.01). This study confirms the association between antibodies to oxidized low density lipoprotein and coronary heart disease and shows raised low density lipoprotein antibody levels in diabetic patients with and without demonstrable atherosclerosis. In the diabetic patients, those with high antibody levels had high polyunsaturated fatty acid levels in their LDL suggesting a possible role for dietary intervention.


๐Ÿ“œ SIMILAR VOLUMES


APOPTOSIS IN HUMAN MONOCYTE-MACROPHAGES
โœ HARDWICK, SIMON J.; HEGYI, LASZLO; CLARE, KATHARINE; LAW, NADINE S.; CARPENTER, ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 1011 KB

This study has demonstrated the toxicity to human monocyte-macrophages of low-density lipoprotein (LDL) which had been artificially oxidized using copper sulphate. The assays of cell damage used were tritiated adenine release, neutral red staining, lactate dehydrogenase leakage, and MTT dye reductio

Negligible synergistic effect of ฮฒ2-glyc
โœ Matsuda, Juzo; Gotoh, Moritaka; Kawasugi, Kazuo; Gohchi, Kengo; Tsukamoto, Miyo; ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 232 KB

We conducted this study to investigate whether antioxidized low-density lipoprotein (a-oxLDL) is an antibody to cryptic and/or neo-antigen on p,-glycoprotein I (GPI), which is introduced by binding to anionic phospholipid, similar to that of GPI-dependent anticardiolipin antibody (aCL) employing a-o

Cholesteryl-ester transfer protein enhan
โœ David Hine; Bharti Mackness; Mike Mackness ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 93 KB

Therapeutic strategies to increase high-density lipoprotein (HDL) to treat or prevent vascular disease include the use of cholesteryl-ester transfer protein (CETP) inhibitors. Here, we show, to the best of our knowledge for the first time, that addition of CETP to HDL enhances the ability of HDL to

Amphotericin B toxicity as related to th
โœ Joanna Barwicz; Isabelle Dumont; Claire Ouellet; Ilona Gruda ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 518 KB

The effect of amphotericin B on the oxidation and degradation of low- and high-density lipoproteins was investigated by UV-vis spectroscopy, electron microscopy, electrophoresis, and size-exclusion chromatography. Two formulations of the drug were used: the commercial Fungizone and a new, less toxic

Contribution of HDL-apolipoproteins to t
โœ Kae-Yuan Lin; Yuh-Lien Chen; Chun-Che Shih; Ju-Pin Pan; Woan-Eng Chan; An-Na Chi ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 318 KB

High-density lipoprotein (HDL) is known as a protective factor against atherosclerosis. However, whether HDL-apolipoproteins (apo-HDL) contribute to the protection in arterial cells remains unclear. The localization patterns of human apolipoproteins in atherosclerotic arteries were determined using